全文获取类型
收费全文 | 2423517篇 |
免费 | 203405篇 |
国内免费 | 7959篇 |
专业分类
耳鼻咽喉 | 34709篇 |
儿科学 | 73782篇 |
妇产科学 | 63507篇 |
基础医学 | 339738篇 |
口腔科学 | 68367篇 |
临床医学 | 222785篇 |
内科学 | 474743篇 |
皮肤病学 | 48504篇 |
神经病学 | 202859篇 |
特种医学 | 97663篇 |
外国民族医学 | 912篇 |
外科学 | 364469篇 |
综合类 | 67612篇 |
现状与发展 | 7篇 |
一般理论 | 983篇 |
预防医学 | 195035篇 |
眼科学 | 56663篇 |
药学 | 184280篇 |
56篇 | |
中国医学 | 8443篇 |
肿瘤学 | 129764篇 |
出版年
2018年 | 25896篇 |
2017年 | 20539篇 |
2016年 | 22155篇 |
2015年 | 25818篇 |
2014年 | 36698篇 |
2013年 | 53909篇 |
2012年 | 73396篇 |
2011年 | 77371篇 |
2010年 | 46251篇 |
2009年 | 43933篇 |
2008年 | 72229篇 |
2007年 | 76323篇 |
2006年 | 76976篇 |
2005年 | 74675篇 |
2004年 | 71145篇 |
2003年 | 68618篇 |
2002年 | 67532篇 |
2001年 | 113374篇 |
2000年 | 117316篇 |
1999年 | 99123篇 |
1998年 | 28335篇 |
1997年 | 26048篇 |
1996年 | 25816篇 |
1995年 | 24918篇 |
1994年 | 23413篇 |
1993年 | 21728篇 |
1992年 | 79570篇 |
1991年 | 76531篇 |
1990年 | 73693篇 |
1989年 | 70975篇 |
1988年 | 65931篇 |
1987年 | 64906篇 |
1986年 | 61404篇 |
1985年 | 58454篇 |
1984年 | 44262篇 |
1983年 | 37681篇 |
1982年 | 22904篇 |
1981年 | 20361篇 |
1979年 | 41314篇 |
1978年 | 29005篇 |
1977年 | 24359篇 |
1976年 | 22843篇 |
1975年 | 23968篇 |
1974年 | 29651篇 |
1973年 | 28050篇 |
1972年 | 26227篇 |
1971年 | 24155篇 |
1970年 | 22755篇 |
1969年 | 21092篇 |
1968年 | 19137篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
111.
背景与目的:CD44分子是众多肿瘤细胞的标志分子,其表达水平与肿瘤细胞的恶性程度有关。该研究探讨CD44基因中的单核苷酸多态性(single nucleotide polymorphism,SNP)位点与云南汉族人群宫颈癌和非小细胞肺癌(nonsmall cell lung cancer,NSCLC)易感性的相关性。方法:选取了CD44基因中的两个SNP位点rs13347和rs8193,采用TagMan基因分型的方法,分析这两个多态性位点在497例宫颈癌患者和500例健康对照个体以及483例NSCLC患者和471例健康对照个体中的分布特征,并分析CD44基因中的多态性位点与云南汉族人群宫颈癌和NSCLC的相关性。结果:rs13347和rs8193位点等位基因和基因型在宫颈癌组和对照组中的分布频率的差异无统计学意义(P>0.05)。而在NSCLC组和对照组的比较中:rs13347和rs8193位点等位基因在NSCLC组和对照组中的分布频率的差异有统计学意义(P=0.020和P=0.004);这两个位点基因型在NSCLC组和对照组中分布频率的差异有统计学意义(P=0.027和P=0.020);其中rs13347位点等位基因C在NSCLC组中的分布频率显著高于对照组,可能是NSCLC发生的风险因素(OR=1.250,95% CI:1.035~1.509),rs8193位点等位基因C在对照组中的分布频率显著高于NSCLC组,可能是NSCLC发生的保护性因素(OR=0.768,95%CI:0.641~0.921)。单倍型分析结果显示,rs13347C-rs8193T和rs13347T-rs8193C在NSCLC组和对照组中的分布频率差异有统计学意义(P=0.003和0.022);该结果说明单倍型rs13347C-rs8193T可能是云南汉族人群NSCLC发生的风险性因素(OR=1.316,95%CI:1.096~1.579)。结论:CD44基因中的两个SNP位点rs13347和rs8193可能与云南汉族人群宫颈癌发病风险无关,而可能与云南汉族人群NSCLC具有相关性。 相似文献
112.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
113.
114.
Changhyun Kim B.S. Brittany G. Craiglow M.D. Kalman L. Watsky M.D. Richard J. Antaya M.D. 《Pediatric dermatology》2015,32(4):e161-e162
A 17‐year‐old boy presented with recurring severe dermatitis of the face of 5‐months duration that resembled impetigo. He had been treated with several courses of antibiotics without improvement. Biopsy showed changes consistent with allergic contact dermatitis and patch testing later revealed sensitization to benzoyl peroxide, which the patient had been using for the treatment of acne vulgaris. 相似文献
115.
116.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
117.
118.
动脉导管未闭(PDA)是早产儿常见疾病,目前早产儿PDA的自然发展过程仍未完全明确,PDA发生的有些高危因素仍存在争议,对PDA是否进行药物、手术干预,以及何时进行药物、手术干预仍存在争议。尽管已经有相当多的证据证实动脉导管持续开放可能有害,但目前尚缺乏关闭导管治疗方案的远期益处或害处的相关证据。大多数临床试验旨在评估短期导管开放对患儿的影响。目前尚无评估动脉导管持续开放对早产儿死亡率及并发症影响的临床试验。近年来PDA治疗上最大的变化是减少对PDA的治疗。该文重点总结胎龄28周早产儿PDA的治疗策略。 相似文献
119.
120.
Marta Rozanski Valentin Neuhaus Emily Thornton Stéphanie J. E. Becker James P. Rathmell David Ring 《Journal of hand and microsurgery》2015,7(1):30-35
This study used the National Survey of Ambulatory Surgery (NSAS) database to measure the incidence of and risk factors for symptoms in the ambulatory surgery center and problems within 24 h after isolated carpal tunnel release (CTR). The NSAS contained records on 400,000 adult patients with carpal tunnel syndrome who were treated with CTR in 2006, based on ICD-9 codes. The type of anesthesia used and factors associated with symptoms and problems were sought in bivariate and multivariable statistical analyses. The mean duration of the procedure was 16 ± 8.8 min. Only 5 % were performed under local anesthesia without sedation, 45 % with IV sedation, 28 % regional anesthesia, and 19 % general anesthesia. Symptoms in the ambulatory surgery center or a problem within 24 h after discharge were recorded in 10 % of patients, all of them minor and transient, including difficulties with pain and its treatment. The strongest risk factors were male sex, age of 45 years and older, and participation of an anesthesiologist. Local anesthesia and regional anesthesia were associated with more perioperative symptoms and postoperative problems. Most CTR are performed with some sedation in the United States. CTR is a safe procedure: one in 10 patients will experience a minor issue in the perioperative or immediate postoperative period. 相似文献